Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-5960

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers ; volume:9 ; number:1 ; day:1 ; month:2 ; year:2021 ; pages:1-15 ; date:12.2021
Acta Neuropathologica Communications ; 9, Heft 1 (1.2.2021), 1-15, 12.2021

Creator: Camporesi, Elena
Lashley, Tammaryn
Gobom, Johan
Lantero-Rodriguez, Juan
Hansson, Oskar
Zetterberg, Henrik
Blennow, Kaj
Becker, Bruno

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40478-021-01119-4

URN: urn:nbn:de:101:1-2021032520271098615786

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Camporesi, Elena
Lashley, Tammaryn
Gobom, Johan
Lantero-Rodriguez, Juan
Hansson, Oskar
Zetterberg, Henrik
Blennow, Kaj
Becker, Bruno
SpringerLink (Online service)

Other Objects (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Related objects

Reset password